The Diabetes-Obesity Continuum: The Growing Body of Evidence for a Multi-hormonal Approach to Treatment CME

Carol Hatch Wysham, MD, FACP, FACE, Chair; Stephen L. Aronoff, MD, FACE; George A. Bray, MD, MACE Author Information and Disclosures

Release Date: December 19, 2007; Valid for credit through December 19, 2008

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "The Diabetes-Obesity Continuum: The Growing Body of Evidence for a Multi-hormonal Approach to Treatment" symposium held at the Hyatt Regency Chicago in Chicago, Illinois, on June 24, 2007.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2007 Medikinetics
Amylin
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Explain the current understanding of the pathophysiology of type 1 diabetes and the potential for a multihormonal treatment approach that mimics normal physiology.
  2. Discuss the physiologic commonalities between obesity and diabetes and how a multihormonal treatment approach might also effectively address obesity.
  3. Describe the natural progression of type 2 diabetes and how a multihormonal treatment approach might benefit patients struggling to manage their disease while controlling body weight.
Authors and Disclosures

Carol Hatch Wysham, MD, FACP, FACE
Disclosure: Grant/Research Support: Amylin; Consultant: Amylin; Speakers' Bureau: Amylin


Stephen L. Aronoff, MD, FACE
Disclosure: Grant/Research Support: Amylin; Speakers' Bureau: Amylin


George A. Bray, MD, MACE
Disclosure: Grant/Research Support: Merck; Consultant: Merck


All additional planning committee members, MediKinetics staff, and Purdue University School of Pharmacy staff have no relationships to disclose.
 
Purdue
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Purdue University School of Pharmacy and MediKinetics. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University School of Pharmacy designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.